A clinical-stage biotechnology company focused on developing therapies for urological and related disorders. Its pipeline has centered on compounds targeting conditions such as overactive bladder, with value largely tied to clinical trial outcomes and potential regulatory approvals. Investors monito...
No congressional trades have been disclosed for Velicept Therapeutics, Inc. (VETH) yet. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
No congressional trades found for this stock.